Real-world dosing data for regorafenib in patients with metastatic colorectal cancer was presented at the 2018 ESMO Congress from the prospective, observational CORRELATE study.
Angelica Welch
Advertisement
Articles by Angelica Welch
Francisco J. Esteva, MD, PhD, discusses the current data surrounding CT-P6 demonstrating its potential as a biosimilar for trastuzumab in the United States.
Advertisement
Latest Updated Articles
Trastuzumab Biosimilar Candidate Shows Promise in Early-Stage Breast CancerPublished: August 31st 2018 | Updated:
Expert Discusses Real-World Data for Regorafenib in mCRCPublished: December 20th 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
